November 2019 - Novaliq

Novaliq and Jiangsu Hengrui Medicine announce a strategic collaboration for the investigational products NOV03 and CyclASol® in China

Jiangsu Hengrui Medicine secures exclusive rights to develop, manufacture, and commercialize NOV03 and CyclASol® in China.
NOV03 (perfluorohexyloctane) is a first-in-class investigational drug with a novel mode of action to treat Dry Eye Disease (DED) associated with Meibomian gland dysfunction (MGD).
CyclASol ® (0.1% cyclosporine A in EyeSol®) is an anti-inflammatory and immunomodulating investigational drug developed for the treatment of aqueous deficient DED.
Novaliq is eligible to receive upfront and milestone payments of up to $165 million plus royalties